

Successful Outcomes in Anal Fistula Treatment Using Ovine Forestomach Matrix Implant Technique



Angela Ting-Wei Hsu¹ MD. MPH., Kevin Schlidt¹ MD., Christopher R. D'Adamo² PhD., Brandon Bosque, DPM³, Shane Dowling MSPAS³, Joshua H. Wolf ¹ MD. Sinai Hospital, Baltimore, MD¹, University of Maryland School of Medicine, Baltimore, MD², Aroa Biosurgery Limited, Auckland, New Zealand³

Background

 Surgical management of cryptoglandular perianal fistulas (PF) is challenging due to high recurrence rates and potential for injury to the sphincter complex with more invasive techniques.

Study Aim

 To assess the safety and efficacy of a non-invasive treatment for PF with a novel biomatrix plug.

Methods

- This is a retrospective observational consecutive case series studying the first nine patients who underwent a noninvasive procedure using ovine forestomach matrix (OFM-implant) in a single center in 2020-2022.
- Exclusion criteria: patients with Crohn's disease.
- Primary outcome was healing at 8th week after procedure.

Figures & Tables

Figure 1. The Ovine Forestomach Matrix Implant




Figure 2. The OFM-implant placement



Table 1. Baseline characteristics and primary outcome

	N=9 cases
Age	64.2 ± 7.6 years old
Gender	7 Male 2 Female
Follow-up period	10.1 ± 4.2 months
Healing at 8 th week	7 out of 9 cases (77.8%)
Recurrence	0%

Results

- 9 patients with average age of 64.2 years.
- 5/9 patients had prior fistula and 3/9 patients had undergone prior surgical intervention.
- All cases were transsphincteric type.
- Healing rate at 8th week was 77.8%.
- Non-healing cases manifested clinically as drainage from the external opening.
- No post-procedural infections or adverse events.

Conclusions

- This OFM-implant closure technique in anal fistula treatment is a safe and feasible non-invasive option for patients with transsphincteric perianal fistulas of cryptoglandular origin.
- Higher efficacy was observed in comparison to published outcomes for other non-invasive methods.
- The efficacy is comparable to invasive surgical techniques such as LIFT and flap procedure.
- A prospective study is planned to validate the preliminary results.

Author Disclosure

- This study was supported by Aroa Biosurgery Limited, Auckland, New Zealand.
- JHW is a paid consultant for Aroa.

